Novartis reported CHF4.42B in Pre-Tax Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Abbvie ABBV:US $ 6290M 282M
Alcon AG ALC:SW 344M 40M
Bayer BAYN:GR € 1537M 1825M
Biogen BIIB:US $ 814.2M 255M
Eli Lilly And LLY:US $ 1988.6M 80.6M
Fresenius FRE:GR € 900M 31M
Fresenius Medical Care FME:GR € 355.01M 42.99M
Genmab GEN:DC DK 422M 1002M
GlaxoSmithKline GSK:LN 1482M 225M
H. Lundbeck A/S LUN:DC 484M 313M
Johnson & Johnson JNJ:US $ 8058M 282M
Lonza Group LONN:SW 496.49M 151.49M
Merck MRK:GR € 1265.8M 32M
Novartis NOVN:VX SF 4424M 620M
Novartis NVS:US $ 4544M 120M
Orion ORNBV:FH € 57.3M 13.1M
Philips PHIA:NA € 523M 352M
Recordati REC:IM € 119.51M 3.51M
Regeneron Pharmaceuticals REGN:US $ 3898.3M 2658.7M
Sanofi SAN:FP € 2180M 376M